Pharmafile Logo

Glaxo SmithKline

- PMLiVE

GSK’s RSV vaccine shows long-term efficacy in late-stage older adults study

Arexvy was recently approved in the EU and US for adults aged 60 years and older

- PMLiVE

AbbVie files patent infringement lawsuit against BeiGene’s blood cancer drug Brukinsa

The BTK inhibitor was approved in the US earlier this year and had its patent issued last week

- PMLiVE

AbbVie announces positive phase 3 results for Skyrizi in ulcerative colitis

Inflammatory bowel disease is estimated to affect nearly one in every 100 people in the US

Boost engagement during virtual events and meetings

Tip #7 - How do you increase engagement during virtual events? Make it fun! ️ See all Top 10 tips: https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/ To learn more, visit us at http://impetusdigital.com/Book a demo today http://www.meetwithimpetus.com/ 

Impetus Digital

- PMLiVE

Novartis to acquire Chinook Therapeutics for approximately $3.5bn

The deal marks a notable expansion to the Swiss drugmaker's kidney disease pipeline

How to Increase Engagement During Virtual Events

Here's tip 8 of 10 on how to increase engagement during virtual events. Learn more tips at  https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/ To find out more about how Impetus Digital can aid pharma and life...

Impetus Digital

- PMLiVE

GSK’s RSV vaccine approved by European Commission for older adults

RSV infections in older adults account for over 170,000 hospitalisations each year in Europe

Navigating patients step by step on their clinical trial journey

For clinical trial participants, navigating their way through a study can sometimes seem daunting and complicated. Without the right support, around 30% are likely to drop out [1], resulting in...

Innovative Trials

- PMLiVE

Innovative Trials responds to national recommendations to tackle UK clinical trial decline

Kate Shaw, Founder & CEO, comments on the Lord report of the Lord O’Shaughnessy review into commercial clinical trials in the UK.

Innovative Trials

- PMLiVE

BMS presents positive four-year results for Opdivo combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

Healing the Healers

Because if we do not heal the healers, who is going to heal us?

Havas Lynx

- PMLiVE

Novartis receives EC approval for Cosentyx in hidradenitis suppurativa

There are around 200,000 people in Europe living with moderate to severe stages of HS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links